Filing Flows › Comparisons › IMDX vs CLDX
Insight Molecular Diagnostics vs Celldex Therapeutics: IMDX and CLDX compared
Insight Molecular Diagnostics is the larger company: $239K of revenue in its latest quarter (Q2 2026) against $22K for Celldex Therapeutics (Q2 2026). Insight Molecular Diagnostics is growing faster (-54% against -97% a year earlier).
Where the money goes: IMDX and CLDX
Insight Molecular Diagnostics (IMDX) · Q2 2026
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
Celldex Therapeutics (CLDX) · Q2 2026
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
| Insight Molecular Diagnostics (IMDX) | Celldex Therapeutics (CLDX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $239K | $22K |
| Revenue growth, Y/Y | -54% | -97% |
| Operating margin | n/m | n/m |
| Net earnings | −$11.3M | −$73.5M |
| Operating cash flow | −$9.3M | −$57.4M |
Where the revenue comes from
Insight Molecular Diagnostics
- Laboratory Services: $218K (91%)
- Kitted Products: $21K (9%)
Celldex Therapeutics
- Contracts and grants: $15K (68%)
- Product development and licensing agreements: $7K (32%)
Questions
Which is bigger, Insight Molecular Diagnostics or Celldex Therapeutics?
Insight Molecular Diagnostics is the larger company: $239K of revenue in its latest quarter (Q2 2026) against $22K for Celldex Therapeutics (Q2 2026).
Is Insight Molecular Diagnostics or Celldex Therapeutics growing faster?
Insight Molecular Diagnostics is growing faster (-54% against -97% a year earlier).
More: Insight Molecular Diagnostics earnings · how Insight Molecular Diagnostics makes money · Celldex Therapeutics earnings · how Celldex Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.